First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 yearsFirst approval of Joenja covering children aged 4 to 11 with APDS Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Jap ...

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Pharming Group N.V. Fourth quarter and full year 2025 financial results March 12, 2026 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM CEO Fabrice Chouraqui Chief Executive Officer Introduction SPEAKERS Fabrice Chouraqui Chief Executive Officer Leverne Marsh Chief Commercial Officer Anurag Relan, MD Chief Medical Officer Kenneth Lynard Chief Financial Officer Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that ar ...

Core Insights - Pharming Group reported strong financial performance for 2025, with significant revenue growth and a return to operating profitability, driven by its products RUCONEST and Joenja [6][5][4] Financial Performance - Total revenue for 2025 reached EUR 376.1 million, reflecting a 27% year-over-year increase, with fourth-quarter revenue of EUR 106.5 million, up 15% from the previous year [4][5] - Adjusted operating profit for 2025 was EUR 36.4 million, a turnaround from a loss of EUR 8.6 million in 2024, while operating cash flow improved to EUR 54.7 million [2][5] - Cash and marketable securities at year-end totaled EUR 181.1 million, despite EUR 68 million used for the Abliva acquisition [2] Product Performance - RUCONEST experienced a 26% year-over-year revenue growth in 2025, with a 9% increase in the fourth quarter, while Joenja's revenue grew 29% for the year and 53% in Q4 [1][4] - Joenja's global revenue for the fourth quarter was $19.8 million, with full-year revenue reaching $58 million, and the number of patients on paid therapy in the U.S. increased by 25% to 120 [9][10] Market Dynamics - The U.S. hereditary angioedema market is seeing new treatment options, but RUCONEST remains resilient, focusing on high-attack patients [7][8] - Pharming noted competitive impacts in Q4 as patients trialed new therapies, with some returning to RUCONEST, indicating a potential for patient switching back to the product [8] Future Guidance - For 2026, Pharming expects revenue growth of EUR 405 million to EUR 425 million, representing an 8% to 13% increase compared to 2025, driven by continued growth in RUCONEST and accelerated growth in Joenja [18] - Operating expenses for 2026 are projected to be between EUR 330 million and EUR 335 million, including over EUR 60 million in R&D investments [21] Pipeline and Regulatory Updates - Pharming is expanding Joenja beyond APDS into additional primary immunodeficiencies, with ongoing phase II trials expected to yield data in the second half of 2026 [13] - The company is addressing regulatory challenges for Joenja's pediatric label expansion and expects to align with the FDA on a resubmission path [15][16]

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnurag Relan - CMOFabrice Chouraqui - CEOJoseph Pantginis - Managing Director, Equity ResearchKenneth Lynard - CFOLaVerne Marsh - Chief Commercial OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior AnalystLucy Codrington - Research AnalystNatalia Webster - AnalystSheila Hernandez - AnalystSimon Scholes - Senior AnalystOperatorGood day, thank you for standing by. Welcome to the Pharmi ...

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnurag Relan - CMOFabrice Chouraqui - CEOJoseph Pantginis - Managing Director, Equity ResearchKenneth Lynard - CFOLaVerne Marsh - Chief Commercial OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior AnalystLucy Codrington - Research AnalystNatalia Webster - AnalystSheila Hernandez - AnalystSimon Scholes - Senior AnalystOperatorGood day, thank you for standing by. Welcome to the Pharmi ...

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Speaker8Good day, thank you for standing by. Welcome to the Pharming Group N.V. fourth quarter and full year 2025 financial results conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, please press star one one on your telephone. You will then hear an automated message advising yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form ...

Core Insights - Pharming Group N.V. reported a strong financial performance for 2025, with total revenues increasing by 27% to US$376.1 million, driven by growth in RUCONEST® and Joenja® [2][7][35] - The company achieved an operating profit of US$25.8 million in 2025, a significant improvement from a loss of US$8.6 million in 2024 [4][40] - Pharming anticipates total revenues for 2026 to be between US$405 million and US$425 million, representing growth of 8% to 13% [4][56] Financial Performance - Total revenues for Q4 2025 increased by 15% to US$106.5 million compared to Q4 2024 [29] - RUCONEST® revenues for the full year 2025 reached US$317.9 million, a 26% increase year-over-year, while Joenja® revenues increased by 29% to US$58.2 million [8][36] - The company reported a net profit of US$2.5 million for 2025, compared to a net loss of US$11.8 million in 2024 [43] Product Performance - RUCONEST® continues to be a key treatment option for patients with HAE, with a 9% revenue increase in Q4 2025 [8][9] - Joenja® saw a 53% revenue increase in Q4 2025, driven by a significant rise in patients on paid therapy in the U.S. [10][11] - The U.S. market accounted for 86% of Pharming's total revenues in 2025, highlighting the importance of this market for the company's growth [11] Pipeline and Future Outlook - Pharming's pipeline includes key upcoming milestones, such as Phase II readouts for leniolisib in broader primary immunodeficiencies expected in the second half of 2026 [6][21] - The company is on track to complete enrollment in the pivotal FALCON study for napazimone (KL1333) in 2026, with data readout anticipated in late 2027 [6][24] - Pharming aims to enhance capital allocation to drive growth and is focused on potential acquisitions and in-licensing opportunities in rare diseases [56]

Core Viewpoint - Pharming Group N.V. will report its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, along with a business update [1]. Group 1: Financial Reporting - The company will provide preliminary financial results for the fourth quarter and full year 2025 [1]. - A conference call and webcast for analysts and investors will be held on the same day at 13:30 CET/08:30 am EDT [1]. Group 2: Participation Details - Registration is required to participate in the conference call or to watch the live webcast [2]. - Dial-in information and a unique PIN will be provided upon registration, and questions will only be taken from dial-in attendees [3]. Group 3: Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare and life-threatening diseases [5]. - The company is headquartered in Leiden, the Netherlands, with a significant number of employees based in the U.S. [5].